115 related articles for article (PubMed ID: 9259397)
21. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
[TBL] [Abstract][Full Text] [Related]
22. Loss of heterozygosity at chromosome 17p is associated with HER-2 amplification and lack of nodal involvement in breast cancer.
Knyazev PG; Imyanitov EN; Chernitsa OI; Nikiforova IF
Int J Cancer; 1993 Jan; 53(1):11-6. PubMed ID: 8416194
[TBL] [Abstract][Full Text] [Related]
23. Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters.
Phelan CM; Borg A; Cuny M; Crichton DN; Baldersson T; Andersen TI; Caligo MA; Lidereau R; Lindblom A; Seitz S; Kelsell D; Hamann U; Rio P; Thorlacius S; Papp J; Olah E; Ponder B; Bignon YJ; Scherneck S; Barkardottir R; Borresen-Dale AL; Eyfjörd J; Theillet C; Thompson AM; Larsson C
Cancer Res; 1998 Mar; 58(5):1004-12. PubMed ID: 9500463
[TBL] [Abstract][Full Text] [Related]
24. Allelic deletion on chromosome 17p13.3 in early ovarian cancer.
Phillips NJ; Ziegler MR; Radford DM; Fair KL; Steinbrueck T; Xynos FP; Donis-Keller H
Cancer Res; 1996 Feb; 56(3):606-11. PubMed ID: 8564979
[TBL] [Abstract][Full Text] [Related]
25. Clonal origin of lymph node metastases in bladder carcinoma.
Jones TD; Carr MD; Eble JN; Wang M; Lopez-Beltran A; Cheng L
Cancer; 2005 Nov; 104(9):1901-10. PubMed ID: 16196038
[TBL] [Abstract][Full Text] [Related]
26. Loss of heterozygosity at D14S62 and metastatic potential of breast cancer.
O'Connell P; Fischbach K; Hilsenbeck S; Mohsin SK; Fuqua SA; Clark GM; Osborne CK; Allred DC
J Natl Cancer Inst; 1999 Aug; 91(16):1391-7. PubMed ID: 10451444
[TBL] [Abstract][Full Text] [Related]
27. Genetic studies of 457 breast cancers. Clinicopathologic parameters compared with genetic alterations.
Harada Y; Katagiri T; Ito I; Akiyama F; Sakamoto G; Kasumi F; Nakamura Y; Emi M
Cancer; 1994 Oct; 74(8):2281-6. PubMed ID: 7922980
[TBL] [Abstract][Full Text] [Related]
28. Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21.
Tavassoli M; Steingrimsdottir H; Pierce E; Jiang X; Alagoz M; Farzaneh F; Campbell IG
Br J Cancer; 1996 Jul; 74(1):115-9. PubMed ID: 8679443
[TBL] [Abstract][Full Text] [Related]
29. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
[TBL] [Abstract][Full Text] [Related]
30. TP53 abnormalities and genetic instability in breast cancer.
Eyfjörd JE; Thorlacius S; Valgardsdottir R; Gretarsdottir S; Steinarsdottir M; Anamthawat-Jonsson K
Acta Oncol; 1995; 34(5):663-7. PubMed ID: 7546836
[TBL] [Abstract][Full Text] [Related]
31. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
Semczuk A; Marzec B; Skomra D; Roessner A; Cybulski M; Rechberger T; Schneider-Stock R
Oncology; 2005; 69(4):317-25. PubMed ID: 16293976
[TBL] [Abstract][Full Text] [Related]
32. Association of genetic alterations on chromosome 17 and loss of hormone receptors in breast cancer.
Ito I; Yoshimoto M; Iwase T; Watanabe S; Katagiri T; Harada Y; Kasumi F; Yasuda S; Mitomi T; Emi M
Br J Cancer; 1995 Mar; 71(3):438-41. PubMed ID: 7880720
[TBL] [Abstract][Full Text] [Related]
33. c-erbB-2 amplification in node-negative human breast cancer.
Ro JS; el-Naggar A; Ro JY; Blick M; Frye D; Fraschini G; Fritsche H; Hortobagyi G
Cancer Res; 1989 Dec; 49(24 Pt 1):6941-4. PubMed ID: 2573424
[TBL] [Abstract][Full Text] [Related]
34. [Amplification of the erbb-2 (Her-2/NEU), erbb-1 (HER-1) and c-myc oncogenes is often combined with the deletion of the short arm of chromosome 17 in human carcinoma].
Imianitov EN; Chernitsa OI; Nikiforova IF; Serova OM; Sokolov SI; Laur OIu; Togo AV; Kniazev PG
Mol Biol (Mosk); 1993; 27(4):888-94. PubMed ID: 8103188
[TBL] [Abstract][Full Text] [Related]
35. Organophosphorous pesticides and estrogen induce transformation of breast cells affecting p53 and c-Ha-ras genes.
Calaf GM; Echiburu-Chau C; Roy D
Int J Oncol; 2009 Nov; 35(5):1061-8. PubMed ID: 19787260
[TBL] [Abstract][Full Text] [Related]
36. Five distinct deleted regions on chromosome 17 defining different subsets of human primary breast tumors.
Nagai MA; Medeiros AC; Brentani MM; Brentani RR; Marques LA; Mazoyer S; Mulligan LM
Oncology; 1995; 52(6):448-53. PubMed ID: 7478429
[TBL] [Abstract][Full Text] [Related]
37. Loss of heterozygosity of p53, BRCA1, VHL, and estrogen receptor genes in breast carcinoma: correlation with related protein products and morphologic features.
Otis CN; Krebs PA; Albuquerque A; Quezado MM; San Juan X; Sobel ME; Merino MJ
Int J Surg Pathol; 2002 Oct; 10(4):237-45. PubMed ID: 12490973
[TBL] [Abstract][Full Text] [Related]
38. Allelic loss of chromosomal arm 8p in breast cancer progression.
Anbazhagan R; Fujii H; Gabrielson E
Am J Pathol; 1998 Mar; 152(3):815-9. PubMed ID: 9502423
[TBL] [Abstract][Full Text] [Related]
39. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.
Lang FF; Miller DC; Koslow M; Newcomb EW
J Neurosurg; 1994 Sep; 81(3):427-36. PubMed ID: 8057151
[TBL] [Abstract][Full Text] [Related]
40. Loss of heterozygosity, microsatellite instability and TP53 gene status in ovarian carcinomas.
Plisiecka-Hałasa J; Dansonka-Mieszkowska A; Kraszewska E; Dańska-Bidzińska A; Kupryjańczyk J
Anticancer Res; 2008; 28(2A):989-96. PubMed ID: 18507046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
